PTGX
Protagonist Therapeutics Inc Earnings
$58.88
Earnings Summary
Revenue | $5.55Mn |
Net Profits | $-34.77Mn |
Net Profit Margins | -626.96% |
PE Ratio | 81.75 |
Protagonist Therapeutics Inc’s revenue jumped 33.09% since last year same period to $5.55Mn in the Q2 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -80.42% fall in its revenue since last 3-months.
Protagonist Therapeutics Inc’s net profit fell -13.57% since last year same period to $-34.77Mn in the Q2 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -198.34% fall in its net profits since last 3-months.
Protagonist Therapeutics Inc’s net profit margin jumped 14.67% since last year same period to -626.96% in the Q2 2025. On a quarterly growth basis, Protagonist Therapeutics Inc has generated -1423.47% fall in its net profit margins since last 3-months.
Protagonist Therapeutics Inc’s price-to-earnings ratio after this Q2 2025 earnings stands at 81.75.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.62 |
EPS Estimate Current Year | -0.62 |
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.62 - a -6.9% fall from last quarter’s estimates.
Protagonist Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.62.
Key Ratios
Earning Per Share (EPS) | 0 |
Protagonist Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Protagonist Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2025-05-06 | 0.11 | -0.19 | -272.73% |
2025-11-05 | -0.62 | 0 | 100% |
2025-08-06 | -0.58 | -0.55 | 5.17% |
